Literature DB >> 32104788

Acute hyperglycemia and contrast-induced nephropathy in patients with non-ST elevation myocardial infarction.

Onur Baydar1, Alparslan Kilic1.   

Abstract

Acute hyperglycemia and contrast-induced nephropathy (CIN) are frequently observed in non-ST elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI), and both are associated with an increased mortality rate. We investigated the possible association between acute hyperglycemia and CIN in patients with NSTEMI undergoing PCI.
MATERIALS AND METHODS: We retrospectively enrolled 281(149, 53% men) NSTEMI patients undergoing PCI. For each patient, plasma glucose levels were secreened at hospital admission. Acute hyperglycemia was defined as glucose levels > 198 mg/dl. CIN was defined as an increase in serum creatinine 25% or 0.5 mg/dl from baseline in the first 48-72 hours.
RESULTS: Overall, 44 (15.7%) patients had acute hyperglycemia. Patients with acute hyperglycemia had higher incidence of CIN than those without acute hyperglycemia (29.5 vs 5.1%, P < 0.001). Also, in-hospital mortality, length of hospital stay, major bleeding, requirement of mechanical ventilation and dialysis were observed significantly higher in patients with hyperglycemia. Patients were then reallocated to two groups according to the presence or absence of CIN. Overall, 25 cases (8.9%) of CIN were diagnosed. Diabetes mellitus, weight, age, glucose level and estimated glomerular filtration rate (eGFR) were detected as independent risk factors of CIN. Additionally, admission glucose levels were significantly correlated with creatinine levels after PCI, eGFR and contrast volume/eGFR ratio.
CONCLUSION: In NSTEMI patients undergoing primary PCI, acute hyperglycemia may be associated with an increased risk for CIN and in-hospital mortality and morbidity.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Keywords:  hyperglycemia; myocardial infarction; nephropathy

Year:  2020        PMID: 32104788      PMCID: PMC7041873          DOI: 10.1097/XCE.0000000000000187

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol Metab        ISSN: 2574-0954


  31 in total

1.  Intensive insulin therapy in critically ill patients.

Authors:  G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

2.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

3.  Risk stratifying chest pain patients in the emergency department using HEART, GRACE and TIMI scores, with a single contemporary troponin result, to predict major adverse cardiac events.

Authors:  Peter D W Reaney; Hamish I Elliott; Awsan Noman; Jamie G Cooper
Journal:  Emerg Med J       Date:  2018-04-05       Impact factor: 2.740

4.  Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era.

Authors:  Masaharu Ishihara; Sunao Kojima; Tomohiro Sakamoto; Yujiro Asada; Chuwa Tei; Kazuo Kimura; Shunichi Miyazaki; Masahiro Sonoda; Kazufumi Tsuchihashi; Masakazu Yamagishi; Yoshihiko Ikeda; Mutsunori Shirai; Hisatoyo Hiraoka; Takeshi Inoue; Fumio Saito; Hisao Ogawa
Journal:  Am Heart J       Date:  2005-10       Impact factor: 4.749

5.  Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.

Authors:  K Malmberg; L Rydén; H Wedel; K Birkeland; A Bootsma; K Dickstein; S Efendic; M Fisher; A Hamsten; J Herlitz; P Hildebrandt; K MacLeod; M Laakso; C Torp-Pedersen; A Waldenström
Journal:  Eur Heart J       Date:  2005-02-23       Impact factor: 29.983

Review 6.  Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.

Authors:  S E Capes; D Hunt; K Malmberg; H C Gerstein
Journal:  Lancet       Date:  2000-03-04       Impact factor: 79.321

7.  Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction.

Authors:  Masaharu Ishihara; Ichiro Inoue; Takuji Kawagoe; Yuji Shimatani; Satoshi Kurisu; Kenji Nishioka; Takashi Umemura; Shuji Nakamura; Masashi Yoshida
Journal:  Am Heart J       Date:  2003-10       Impact factor: 4.749

Review 8.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

9.  Hyperglycaemia following acute myocardial infarction: the contribution of undiagnosed diabetes.

Authors:  G A Oswald; J S Yudkin
Journal:  Diabet Med       Date:  1987 Jan-Feb       Impact factor: 4.359

10.  Impact of acute hyperglycemia during primary stent implantation in patients with ST-elevation myocardial infarction.

Authors:  Tomohiro Nakamura; Junya Ako; Tomoko Kadowaki; Hiroshi Funayama; Yoshitaka Sugawara; Norifumi Kubo; Shinichi Momomura
Journal:  J Cardiol       Date:  2009-01-18       Impact factor: 3.159

View more
  2 in total

1.  Predictive Value of Lymphocyte-to-monocyte Ratio in Patients with Contrast-induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome.

Authors:  Irem Karauzum; Kurtulus Karauzum; Burak Acar; Kaan Hanci; Halil Ibrahim Ulas Bildirici; Teoman Kilic; Ertan Ural
Journal:  J Transl Int Med       Date:  2021-07-09

2.  Admission hyperglycemia as an independent predictor of long-term prognosis in acute myocardial infarction patients without diabetes: A retrospective study.

Authors:  Cai-Yan Cui; Ming-Gang Zhou; Lian-Chao Cheng; Tao Ye; Yu-Mei Zhang; Feng Zhu; Si-Yi Li; Xing-Lin Jiang; Qiang Chen; Ling-Yao Qi; Xu Chen; Si-Qi Yang; Lin Cai
Journal:  J Diabetes Investig       Date:  2020-12-28       Impact factor: 4.232

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.